Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 August 2020 | Story Andre Damons
Follow these three easy steps to enter the Three-Minute Thesis Competition. Will you be this year’s winner?

 

The Three-Minute Thesis Competition, also known as the ‘3MT’, is an annual competition held at 200 universities around the world. It is open to PhD and master’s students, and challenges participants to present their research in just 180 seconds – in a way that is understood by an audience with no background in the research area. 


The UFS Postgraduate School was the first to bring the ‘Three-Minute Thesis’ (3MT) competition to Africa. The Three-Minute Thesis competition originates from the University of Queensland, Australia, and has now become an annual event at the UFS.

The competition aims to help participants develop presentation, research, and academic communication skills, as well as to support the development of research students’ ability to effectively explain their work. 
Although our country is in the midst of a pandemic, the annual competition continues. This year’s Three-Minute Thesis competition will be hosted online at
- The competition will first be hosted at the faculty level; faculty entries close at 14 August 2020

- Winners at faculty level will compete against each other at the Institutional level on 9 October 2020 and will stand a chance at winning these awesome cash prizes

UFS INSTITUTIONAL PRIZES FOR 2020 ARE:

Position Prizes 2020
Master’s winner R6 000
Master’s 1st runner-up R4 000
Master’s 2nd runner-up R2 000
PhD winner  R8 000
PhD 1st runner-up R6 000
PhD 2nd runner-up R4 000

 

Institutional winners will compete against other universities at the national level on 6 November 2020.


News Archive

Death may come in adorable little packages
2015-03-23

The main host of the Lassa virus is the Natal Mulimammate mouse.

Photo: Supplied

Postdoctoral researcher, Abdon Atangana, of the Institute for Groundwater Studies at the university recently published an article online about the Lassa Haemorrhagic fever in the Natural Computing Applications Forum. In addition to the terminal transmissible sickness recognised as Ebola haemorrhagic fever, there is another strain called Lassa haemorrhagic fever.

The disease is classified under the arenaviridae virus family. The first outbreaks of the disease were observed in Nigeria, Liberia, Sierra Leone, and the Central African Republic. However, it was first described in 1969 in the town of Lassa, in Borno State, Nigeria.

The main host of the Lassa virus is the Natal Mulimammate mouse, an animal indigenous to most of Sub-Saharan Africa. The contamination in humans characteristically takes place through exposure to animal excrement through the respiratory or gastrointestinal tracts.

Mouthfuls of air containing tiny particle of infective material are understood to be the most noteworthy way of exposure. It is also possible to acquire the infection through broken skin or mucous membranes that are directly exposed to the infective material.

“The aim of my research was to propose a novel mathematical equation used to describe the spread of the illness amongst pregnant women in West Africa. To achieve this, I used my newly-proposed derivative with fractional order called beta-derivative. Since none of the commonly used integral transform could be used to derive the solution of the proposed model, I proposed a new integral transform called Atangana-Transform, and used it, together with some iterative technique, to derive the solution of the model.

“My numerical simulations show that the disease is as deadly amongst pregnant women as Ebola,” Abdon said.

Abdon’s research was submitted to one of Springer’s top-tier journals with an impact factor 1.78. The paper was accepted and published February 2015.

Read more about Abdon’s research.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept